
J B Chemicals & Pharmaceuticals Ltd Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Domestic India business is expected to grow at 12% to 14% annually, outpacing the market growth of 8%-12%.
- Chronic portfolio in India is growing strongly at 18%, compared to 10% market growth, and is a key growth driver.
- Acute portfolio growth is modest at around 6%-7%, with better traction expected in upcoming quarters.
- International business, excluding South Africa, grew mid-teens; overall international business expected to grow at healthy double digits (~12%) next year after South Africa base reset.
- CDMO business aims to reach close to $100 million revenue in about three years, supported by new product launches and portfolio diversification.
- Volume growth in India is approximately 5%-6%, balanced evenly with pricing growth.
- New launches, especially in CDMO, expected in the second half of next year, supporting future growth.
- The company targets increasing contribution from India and CDMO to 75%-80% of overall sales in mid to long term.
See what J B Chemicals & Pharmaceuticals Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The company has not indicated any current plans for new fundraising through debt or equity.
- It reported a significant reduction in gross debt from Rs.548 crore (March 2023) to Rs.427 crore (September 2023) and net debt down to Rs.18 crore.
- The company is generating strong cash flows (around Rs.500 crore annually).
- Management separates debt and M&A plans, indicating no long-term debt concerns.
- There is no mention of immediate equity fundraising.
- CAPEX plans for the year are funded from internal resources, including Rs.145 crore planned for facility expansion.
- Overall, the focus appears to be on organic growth, selective inorganic acquisitions funded via internal accruals, and maintaining a strong balance sheet rather than raising new external capital.
See what J B Chemicals & Pharmaceuticals Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Current FY24 CAPEX guidance is Rs.145 crore, including:
- - Rs.50 crore for land acquisition adjacent to the current lozenges manufacturing unit (futuristic expansion).
- - Around Rs.70 crore is maintenance CAPEX.
- - Marginal expansion of granulation tablet unit.
- Land acquisition is in preparation for doubling manufacturing capacity over 2-3 years.
- No immediate plans to add new medical reps, focusing on productivity growth.
- Exploring expansion in international geographies like the Philippines, but no near-term costs or launches expected (1-2 years away).
- CDMO business is growing, aiming to double revenue to $100 million in mid to long term via portfolio expansion, new geographies, cost savings, and new product launches.
- Company remains open to inorganic growth via bolt-on acquisitions aligned with strategic focus, maintaining a payback period target of under 6 years.
Track J B Chemicals & Pharmaceuticals Ltd — get its next earnings analysis in your feed
How does J B Chemicals & Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does J B Chemicals & Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare J B Chemicals & Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What J B Chemicals & Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem